Hotez Emily, Chua Kristine J, Samras Nathan, Smith Andrew M, Kuo Alice
General Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, USA.
Cureus. 2023 May 4;15(5):e38541. doi: 10.7759/cureus.38541. eCollection 2023 May.
In the United States, one in six children has an intellectual and/or developmental disability (I/DD), including attention deficit hyperactivity disorder (ADHD), autism, cerebral palsy, learning disabilities, seizures, and developmental delays, with or without intellectual impairment. Individuals with I/DDs experience disproportionate rates of immune, metabolic, cardiovascular, and neurological disorders, as well as anxiety, depression, functional somatic symptoms, and other co-occurring physical and mental health conditions. During the coronavirus disease 2019 (COVID-19) pandemic, having an I/DD emerged as one of the strongest predictors of contracting and dying from COVID-19. These findings spurred increased attention toward the myriad health inequities affecting this population well before the pandemic. While inequities for individuals with I/DD can be traced to many factors, social determinants of health (SDOH) - the underlying social, economic, and environmental conditions that lead to poor health outcomes and high healthcare costs - are key contributors. Our interdisciplinary combined internal medicine and pediatrics (Med-Peds) team of physicians, psychologists, and researchers within a large, diverse, academic health system aimed to pilot-test the implementation of a five-item SDOH screener within a Med-Peds specialty clinic focused on the developmental needs of individuals with I/DD and their families (Leadership Education in Neurodevelopmental Disabilities {LEND}) and a general primary care practice (PCP). The SDOH screener tested in this initiative includes five items from the Accountable Health Communities (AHC) Health-Related Social Needs Screening Tool (HRSN) assessing social isolation, food insecurity, transportation, and paying for basic needs, such as housing and medical care. In this study, we describe the process of implementing this screener and collecting initial pilot data from 747 patients between October 2022 and April 2023 across the LEND and the primary care practice. We also highlight the challenges and opportunities identified during the mid-way point of implementation and pilot testing. The results of this pilot study revealed low response rates among SDOH screeners, spurring several measures to increase uptake, including increasing the accessibility of the screener and ensuring the screener results in effective referrals. We call on additional Med-Peds healthcare teams without universal SDOH screening protocols in place - particularly those serving the I/DD population - to consider adopting these practices.
在美国,每六个孩子中就有一个患有智力和/或发育障碍(I/DD),包括注意力缺陷多动障碍(ADHD)、自闭症、脑瘫、学习障碍、癫痫和发育迟缓,无论是否伴有智力障碍。患有I/DD的个体患免疫、代谢、心血管和神经疾病的比例过高,同时还伴有焦虑、抑郁、功能性躯体症状以及其他身心健康问题。在2019冠状病毒病(COVID-19)大流行期间,患有I/DD成为感染COVID-19并死于该病的最强预测因素之一。早在大流行之前,这些发现就促使人们更加关注影响这一人群的众多健康不平等问题。虽然I/DD患者的不平等可追溯到许多因素,但健康的社会决定因素(SDOH)——导致健康状况不佳和医疗成本高昂的潜在社会、经济和环境条件——是关键因素。我们的跨学科内科和儿科(Med-Peds)团队由医生、心理学家和研究人员组成,来自一个大型、多元化的学术健康系统,旨在对在一个专注于I/DD患者及其家庭发展需求的Med-Peds专科诊所(神经发育障碍领导力教育{LEND})和一个普通初级保健机构(PCP)中实施一项五项SDOH筛查工具进行试点测试。本倡议中测试的SDOH筛查工具包括来自可问责健康社区(AHC)健康相关社会需求筛查工具(HRSN)的五个项目,用于评估社会隔离、粮食不安全、交通以及支付住房和医疗等基本需求的费用。在本研究中,我们描述了实施该筛查工具的过程,并收集了2022年10月至2023年4月期间LEND和初级保健机构中747名患者的初步试点数据。我们还强调了在实施和试点测试中期发现的挑战和机遇。这项试点研究的结果显示,SDOH筛查工具的回应率较低,这促使采取了多项措施来提高参与度,包括提高筛查工具的可及性并确保筛查结果能有效转诊。我们呼吁其他尚未制定通用SDOH筛查方案的Med-Peds医疗团队——尤其是那些服务于I/DD人群的团队——考虑采用这些做法。